volume 67 pages 101764

Cross-presentation by the others

François-Xavier Mauvais 1, 2
Peter van Endert 2, 3
1
 
Service de Physiologie – Explorations Fonctionnelles Pédiatriques, AP-HP, Hôpital Universitaire Robert Debré, F-75019 Paris, France
3
 
Service Immunologie Biologique, AP-HP, Hôpital Universitaire Necker-Enfants Malades, F-75015 Paris, France
Publication typeJournal Article
Publication date2023-05-01
scimago Q1
wos Q1
SJR3.417
CiteScore14.9
Impact factor7.8
ISSN10445323, 10963618
Immunology
Immunology and Allergy
Abstract
The critical role of conventional dendritic cells in physiological cross-priming of immune responses to tumors and pathogens is widely documented and beyond doubt. However, there is ample evidence that a wide range of other cell types can also acquire the capacity to cross-present. These include not only other myeloid cells such as plasmacytoid dendritic cells, macrophages and neutrophils, but also lymphoid populations, endothelial and epithelial cells and stromal cells including fibroblasts. The aim of this review is to provide an overview of the relevant literature that analyzes each report cited for the antigens and readouts used, mechanistic insight and in vivo experimentation addressing physiological relevance. As this analysis shows, many reports rely on the exceptionally sensitive recognition of an ovalbumin peptide by a transgenic T cell receptor, with results that therefore cannot always be extrapolated to physiological settings. Mechanistic studies remain basic in most cases but reveal that the cytosolic pathway is dominant across many cell types, while vacuolar processing is most encountered in macrophages. Studies addressing physiological relevance rigorously remain exceptional but suggest that cross-presentation by non-dendritic cells may have significant impact in anti-tumor immunity and autoimmunity.
Found 
Found 

Top-30

Journals

1
2
Frontiers in Immunology
2 publications, 15.38%
Biomedicine and Pharmacotherapy
1 publication, 7.69%
Advances in Immunology
1 publication, 7.69%
Frontiers in Oncology
1 publication, 7.69%
International Journal of Molecular Sciences
1 publication, 7.69%
Cell Reports
1 publication, 7.69%
International Immunopharmacology
1 publication, 7.69%
Advanced Science
1 publication, 7.69%
Immunology and Cell Biology
1 publication, 7.69%
Immunology Letters
1 publication, 7.69%
1
2

Publishers

1
2
3
4
5
Elsevier
5 publications, 38.46%
Frontiers Media S.A.
3 publications, 23.08%
Wiley
2 publications, 15.38%
MDPI
1 publication, 7.69%
1
2
3
4
5
  • We do not take into account publications without a DOI.
  • Statistics recalculated weekly.

Are you a researcher?

Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
13
Share
Cite this
GOST |
Cite this
GOST Copy
Mauvais F. et al. Cross-presentation by the others // Seminars in Immunology. 2023. Vol. 67. p. 101764.
GOST all authors (up to 50) Copy
Mauvais F., van Endert P. Cross-presentation by the others // Seminars in Immunology. 2023. Vol. 67. p. 101764.
RIS |
Cite this
RIS Copy
TY - JOUR
DO - 10.1016/j.smim.2023.101764
UR - https://doi.org/10.1016/j.smim.2023.101764
TI - Cross-presentation by the others
T2 - Seminars in Immunology
AU - Mauvais, François-Xavier
AU - van Endert, Peter
PY - 2023
DA - 2023/05/01
PB - Elsevier
SP - 101764
VL - 67
PMID - 37084655
SN - 1044-5323
SN - 1096-3618
ER -
BibTex
Cite this
BibTex (up to 50 authors) Copy
@article{2023_Mauvais,
author = {François-Xavier Mauvais and Peter van Endert},
title = {Cross-presentation by the others},
journal = {Seminars in Immunology},
year = {2023},
volume = {67},
publisher = {Elsevier},
month = {may},
url = {https://doi.org/10.1016/j.smim.2023.101764},
pages = {101764},
doi = {10.1016/j.smim.2023.101764}
}